CAMP
What one share of CAMP4 Therapeutics holds
Pharmaceutical Preparations
We are a clinical-stage biopharmaceutical company pioneering the discovery and development of a new class of RNA-targeting therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a broad range of genetic diseases.
CAMP4 Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.09 |
|---|---|
| Profit | −$2.18 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.58 |
| Cash and investments | $1.66 |
| Book value | −$0.01 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | $0.89 | −$124.79 | $1.72 | −$113.51 | — | −$268.57 |
| 2024 | $0.14 | −$11.04 | $0.09 | −$9.81 | $0.00 | — |
| 2025 | $0.12 | −$2.65 | $0.01 | −$0.98 | $0.00 | $0.92 |